Technical Analysis for ADXS - Advaxis, Inc.

Grade Last Price % Change Price Change
grade F 2.94 -0.34% -0.01
ADXS closed down 0.34 percent on Friday, May 24, 2019, on 7 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Jun 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ADXS trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Outside Day Range Expansion -0.34%
Wide Bands Range Expansion -0.34%
Oversold Stochastic Weakness -0.34%
Narrow Range Bar Range Contraction 0.68%
Lower Bollinger Band Walk Weakness 0.68%

Older signals for ADXS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company's platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The company's products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey.
Medicine Biotechnology Cancer Infectious Diseases Cancers Prostate Cancer Tumor Immunotherapies Infectious Causes Of Cancer Platform Technology Head And Neck Cancer Cancer Vaccine Human Papillomavirus Infection Osteosarcoma Cervical Cancer Anal Cancer
Is ADXS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.4
52 Week Low 2.7
Average Volume 634,795
200-Day Moving Average 8.1649
50-Day Moving Average 4.291
20-Day Moving Average 3.2812
10-Day Moving Average 3.045
Average True Range 0.2829
ADX 9.4
+DI 23.6021
-DI 25.0752
Chandelier Exit (Long, 3 ATRs ) 2.9213
Chandelier Exit (Short, 3 ATRs ) 3.6887
Upper Bollinger Band 3.7967
Lower Bollinger Band 2.7657
Percent B (%b) 0.17
BandWidth 31.421431
MACD Line -0.3164
MACD Signal Line -0.3398
MACD Histogram 0.0233
Fundamentals Value
Market Cap 120.73 Million
Num Shares 41.1 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -1.28
Price-to-Sales 9.06
Price-to-Book 1.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.09
Resistance 3 (R3) 3.10 3.06 3.07
Resistance 2 (R2) 3.06 3.02 3.06 3.06
Resistance 1 (R1) 3.00 3.00 2.98 2.99 3.05
Pivot Point 2.96 2.96 2.95 2.96 2.96
Support 1 (S1) 2.90 2.92 2.88 2.89 2.83
Support 2 (S2) 2.86 2.90 2.86 2.82
Support 3 (S3) 2.80 2.86 2.82
Support 4 (S4) 2.79